Skip to main content

Table 3 Multivariate logistic regression models to examine the effect of cytomegalovirus diseases on the development of moderate-to-severe dementia according to sex and age distribution

From: Association between cytomegalovirus end-organ diseases and moderate-to-severe dementia: a population-based cohort study

Type of dementia Subgroups CMV diseases Number of participants Events IRa OR (95% CI) P-value
Model 1 Model 2 Model 3
All Sex M No 1950 42 5.20 1 (Ref.) 1 (Ref.) 1 (Ref.) 0.648
Yes 390 17 11.45 2.19 (1.25–3.85) 2.26 (1.27–3.99) 2.02 (1.09–3.59)
F No 1485 63 10.50 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 297 21 19.46 1.86 (1.13–3.04) 1.91 (1.09–3.12) 1.93 (1.14–3.23)
Age 40–59 No 2030 3 0.35 1 (Ref.) 1 (Ref.) 1 (Ref.) 0.025
Yes 406 7 4.28 12.31 (3.18–47.60) 12.47 (3.14–48.76) 11.68 (2.45–49.37)
60–79 No 1260 62 12.47 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 252 21 24.48 1.97 (1.20–3.24) 2.00 (1.21–3.34) 1.83 (1.07–3.15)
≥ 80 No 145 40 86.74 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 29 10 145.71 1.62 (0.81–3.24) 1.38 (0.69–2.88) 1.31 (0.49–2.83)
AD Sex M No 1950 29 3.59 1 (Ref.) 1 (Ref.) 1 (Ref.) 0.197
Yes 390 13 8.76 2.44 (1.27–4.69) 2.47 (1.25–4.72) 2.37 (1.21–4.62)
F No 1485 48 8.00 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 297 10 9.27 1.17 (0.59–2.31) 1.22 (0.60–2.45) 1.28 (0.61–2.59)
Age 40–59 No 2030 2 0.23 1 (Ref.) 1 (Ref.) 1 (Ref.) 0.037
Yes 406 4 2.44 10.57 (1.94–57.69) 10.62 (1.88–58.76) 13.59 (2.14–86.26)
60–79 No 1260 46 9.25 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 252 14 16.32 1.80 (0.99–3.27) 1.89 (1.01–3.45) 1.77 (0.99–3.30)
≥ 80 No 145 29 62.89 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 29 5 72.85 1.14 (0.44–2.96) 1.02 (0.36–2.70) 1.01 (0.33–2.76)
VaD Sex M No 1950 7 0.87 1 (Ref.) 1 (Ref.) 1 (Ref.) 0.243
Yes 390 2 1.35 1.52 (0.32–7.32) 1.58 (0.29–7.90) 1.27 (0.19–6.54)
F No 1485 5 0.83 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 297 5 4.63 5.47 (1.58–18.88) 5.42 (1.47–17.87) 4.31 (1.08–16.51)
Age 40–59 No 2030 1 0.12 1 (Ref.) 1 (Ref.) 1 (Ref.) 0.781
Yes 406 1 0.61 5.21 (0.33–83.36) 5.24 (0.28–78.93) 1.18 (0.05–23.31)
60–79 No 1260 7 1.41 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 252 3 3.50 2.40 (0.62–9.26) 2.44 (0.60–9.52) 1.83 (0.36–7.69)
≥ 80 No 145 4 8.67 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 29 3 43.71 4.66 (1.04–20.90) 4.34 (0.82–17.59) 5.29 (0.78–31.74)
Others Sex M No 1950 6 0.74 1 (Ref.) 1 (Ref.) 1 (Ref.) 0.642
Yes 390 2 1.35 1.80 (0.36–8.92) 1.82 (0.23–9.43) 1.56 (0.21–7.96)
F No 1485 10 1.67 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 297 6 5.56 3.28 (1.19–9.03) 3.15 (1.07–8.77) 3.15 (1.05–9.23)
Age 40–59 No 2030 0 0.0
Yes 406 2 1.22
60–79 No 1260 9 1.81 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 252 4 4.66 2.52 (0.77–8.17) 2.37 (0.65–8.37) 2.41 (0.68–8.29)
≥ 80 No 145 7 15.18 1 (Ref.) 1 (Ref.) 1 (Ref.)
Yes 29 2 29.14 1.74 (0.36–8.41) 1.19 (0.20–6.21) 1.31 (0.23–7.03)
  1. Data are expressed as number or OR (95% CI). Events indicate the new-onset moderate-to-severe dementia. Model 1, non-adjusted; Model 2, age-, sex-, low income status, and BMI-adjusted; Model 3, age-, sex-, low income status-, BMI-, SOT recipients-, HSCT recipients-, malignant neoplasms-, ESRD on dialysis-, NIDDM-, hypertension-, and dyslipidaemia-adjusted
  2. Abbreviations; AD Alzheimer’s disease, BMI body mass index, CI confidence interval, CMV cytomegalovirus, ESRD end-stage renal disease, F female, HSCT haematopoietic stem cell transplantation, IR incidence rate, M male, No number of patients, NIDDM non-insulin-dependent diabetes mellitus, OR odds ratio, Ref. reference, SOT solid organ transplantation; VaD vascular dementia
  3. aPer 1000 person-years